# **Supplementary Appendix for:** Natural History of Untreated Pulmonary Tuberculosis in Adults: A Systematic Review and Meta-Analysis

Bianca Sossen (MBChB)<sup>1,2,#</sup>, Alexandra Richards (MMathPhys)<sup>3,4,#</sup>, Torben Heinsohn (BMBCh)<sup>2,5</sup>, Beatrice Frascella (MD)<sup>6</sup>, Federica Balzarini (MD)<sup>6</sup>, Aurea Oradini-Alacreu (MD)<sup>6</sup>, Prof. Anna Odone (PhD)<sup>7</sup>, Ewelina Rogozinska (PhD)<sup>8</sup>, Brit Häcker (Dr)<sup>9</sup>, Prof. Frank Cobelens (PhD)<sup>10,11</sup>, Prof. Katharina Kranzer (PhD)<sup>12-14</sup>, Prof. Rein MGJ Houben (PhD)<sup>3,4;&</sup>, Hanif Esmail (PhD)<sup>2,8,15;&,¥</sup>

<sup>1</sup> Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

<sup>2</sup> Institute for Global Health, University College London, London, UK

<sup>3</sup> TB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK

<sup>4</sup> Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Public Health, London

School of Hygiene and Tropical Medicine, London, UK

<sup>5</sup> Helmholtz Centre for Infection Research, Department of Epidemiology

<sup>6</sup> School of Public Health, Vita-Salute San Raffaele University, Milan, Italy

<sup>7</sup> Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy

<sup>8</sup> MRC Clinical Trials Unit at University College London, UK

<sup>9</sup> German Central Committee against Tuberculosis (DZK), Berlin, German

<sup>10</sup> Amsterdam University Medical Centers location University of Amsterdam, Department of Global Health

<sup>11</sup> Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

<sup>12</sup> Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, UK

- <sup>13</sup> Biomedical Research and Training Institute, Harare, Zimbabwe
- <sup>14</sup> Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- <sup>15</sup> Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa
- # Contributed Equally

& Contributed Equally

¥ Corresponding Author: Dr Hanif Esmail at MRC Clinical Trials Unit, 90 High Holborn, London, WC1V 6LJ or h.esmail@ucl.ac.uk

## Table of Contents

Supplementary Table 1: Adapted Newcastle Ottawa Quality Assessment Tool	3
Supplementary Table 2: Bias Assessment	6
Supplementary Table 3: Extracted studies	7
Supplementary Table 4: Descriptors on imaging assessments	. 18
Supplementary Table 5: Descriptors of cohorts included in the Systematic Review	. 21
Supplementary Figure 1: Micro negative to positive, in those studies that used culture	. 23
Supplementary Figure 2: Micro negative to positive, stratified by symptom and CXR status at baseline	. 24
Supplementary Figure 3: CXR negative and Micro negative, to Micro positive	. 25
Supplementary Figure 4: Micro negative to positive, stratified by structure of follow up	. 26
Full Search Strategy: English	. 27
Full Search Strategy: German	. 29
PRISMA Checklist(39)	. 30
References	. 32

# Supplementary Table 1: Adapted Newcastle Ottawa Quality Assessment Tool

GENERAL QUALITY ASSESSMENT	MAXIMUM STARS
STUDY SELECTION	
1. Representativeness of 'exposed' cohort	
Truly representative of general population e.g. identified through prospective recruitment following mass screening or household screening	1 star
Somewhat representative of general population e.g. identified through occupational screening	
Selected group e.g. sanatorium or hospital patients	0 stars
No description of the derivation of the cohort	U Stars
2. Selection of non-exposed cohort	
NOT APPLICABLE	
3. Ascertainment of exposure* Documented TST conversion	
Exposure appropriately inferred from significant exposure to active TB e.g. in household or occupational setting	1 star
No clear significant exposure to active TB	0 -+
No description	0 stars
4. Demonstration that outcome of interest not present at start of study*	
Yes - evidence of TB excluded by CXR at beginning of follow-up, or documented as not being present on CXR within previous 12 months	1 star
Not stated	0 stars
COMPARABILITY	
NOT APPLICABLE OUTCOME	
5. Assessment of outcome	
Disease defined on the basis of microbiological demonstration of organism	1 star
Disease defined without microbiological evidence	<b>a</b> .
No description	0 stars
6. Could intervention prevent development of outcome	
No medical or surgical treatment provided	
Medical or surgical treatment provided to a subgroup of clearly identified individuals analysed separately and no selection bias	1 star
Medical or surgical treatment provided to a subgroup (<10%) and that treatment deemed unlikely to influence outcome	
Medical or surgical treatment provided to a large number of individuals OR unable to be analysed separately OR selection bias	0 stars
7. Was total follow-up long enough for outcomes to occur	
Yes - follow-up equal to or longer than 12 months	1 star
No A desus su of follow up of esherts	0 stars
8. Adequacy of follow-up of cohorts Complete follow-up	
Participants lost to follow up unlikely to introduce bias: <20% of participants lost to follow-up per annum, or description provided for those lost, making introduction of bias unlikely	1 star
Lost to follow-up rate > 20% per annum and no description of those lost No statement	0 stars

\* These sections were only applicable to those cohorts of patients that started with CXR and microbiology negative for TB

ADDITIONAL SPECIFIC QUALITY ASSESSMENT - If study meets general quality criteria above, used to determine if microbiological, radiographic and symptoms are recorded to sufficient quality	MAXIMUM STARS
RADIOGRAPHY	
1. Technology	r
Radiography (X-Ray, Roentgenography)	1 star
Mass Miniature radiography (Photofluorography, Aburography)	
Other (please specify)	0 stars
2. Diagnostic criteria used	
Clear use of recognised diagnostic criteria (e.g. ATS)	1 star
Clear description of study specific methodology (not recognised diagnostic criteria)	1 3101
No or limited description of criteria or methodology	0 stars
No imaging	0 51015
3. Methodology	
Double or triple independent read	1 star
Single reader	0 stars
Not specified	U Stars
4. Follow-up	
Complete follow-up	
<20% of participants per annum in follow-up did not receive imaging OR description for those not receiving imaging, making introduction of bias unlikely	1 star
<80% followed up received imaging and no description of those lost	0 stars
No statement	0 51015
MICROBIOLOGY	
1. Technology	
Culture - solid	
Culture - liquid	
Smear - with concentration	1 star
Smear - without concentration	1 5101
Guinea pig inoculation	
Other (please specify)	
Not specified	0 stars
2. Sampling method	
24-hour sputum collection	
48-hour sputum collection	
72-hour sputum collection	
Induced sputum (e.g. physiotherapy or saline)	1
Spot sputum collection (including <24 hour collection	1 star
Gastric aspirate	
Nasal/Laryngeal/Tracheal swab	
Other (please specify)	
Not specified	0 stars
	1

Complete follow-up of those able to produce sputum <20% of per annum of participants had sputum collected (of those able to produce) for microbiological investigation OR description provided for that lost, making introduction of bias unlikely	1 star		
Follow-up rate <80% and no description of those lost No statement	0 stars		
SYMPTOMS			
1. Methodology			
Standardised symptom screen described in methodology			
Clear statement of symptomatic vs asymptomatic	1 star		
Standardised definitions from published criteria used with symptoms included in definition	]		
No clear statement	0 stars		
2. Follow-up			
Complete follow-up			
<20% of participants per annum in follow-up did not get symptom assessment OR description provided for those lost, making introduction of bias unlikely	1 star		
Follow-up rate <80% and no description of those lost No statement	0 stars		

## Supplementary Table 2: Bias Assessment

	General Quality	y Assessment <sup>+</sup>	Specific Quality Assessment				
	Study Selection‡	Outcome Assessment	Radiography	Microbiology	Symptoms		
1. Alling(21)	0	0 0 0 X	0 0 0 X	0 0 <b>X</b>	0 X		
2. Anastasatu(22)	X	0000	0 0 <b>X X</b>	000	ХХ		
3. Aneja(23)	0	0000	0000	000	0 0		
4. Beeuwkes(24)	0	0 0 0 X	0 0 <b>X X</b>	0 0 <b>X</b>	0 <b>X</b>		
5. Bobrowitz(25,26)	X	0000	0000	000	0 0		
6. Borgen(27,28)	000	0000	0 0 0 X	0 0 <b>X</b>	0 0		
7. Breu(29)	0	0000	0 0 0 X	000	ХХ		
8. Cowie(30)	0	0000	0 0 0 X	000	ХХ		
9. Downes(31)	X	0 0 0 X	0 0 0 X	XXX	0 0		
10. Frimodt- Moller(32)	0	0000	0000	000	ХХ		
11. Hong Kong Chest Service(33– 36)	x	0000	0 0 0 X	000	0 0		
12. IUAT Committee on Prophylaxis(37)	x	0000	0 0 0 <b>X</b>	000	ХХ		
13. Lincoln(21,38)	0	0 0 0 X	0 0 0 <b>X</b>	0 0 <b>X</b>	0 <b>X</b>		
14. Manser(39)	X	0 0 0 X	0 0 0 <b>X</b>	000	0 0		
15. Marshall(40)	0	0000	0000	000	0 0		
16. National Tuberculosis Institute(41–49)	000	0000	0000	000	ХХ		
17. Norregaard(50)	X	0000	0 0 0 <b>X</b>	000	0 X		
18. Okada(51)	0 0 <b>X</b>	0000	0000	000	0 0		
19. Orrego Puelma(52)	X	0000	0 0 0 <b>X</b>	000	0 X		
20. Pamra(53)	0	0000	0 0 0 X	000	ХХ		
21. Puffer(54)	0	0 0 0 X	0 0 0 X	XXX	ХХ		
22. Sikand(55)	000	0 0 0 X	0 0 0 X	000	ХХ		
23. Styblo(56)	000	0 0 X X	0 0 0 X	0 0 <b>X</b>	0 X		
24. Tuberculosis Society of Scotland(57,58)	x	0000	0 0 0 <b>X</b>	000	XX		

\* This table only includes the quality assessments for studies included in the meta-analysis, with a 0 representing a positive score and X representing a negative score.

+ Studies could only lose two stars in the General Quality Assessment to proceed to data extraction. Further details of the quality assessment tools are available in supplementary material.

<sup>‡</sup> Studies could score a maximum of 3 stars if participants entered the cohort with no evidence of disease (chest x-ray negative, microbiologically negative and asymptomatic) or a maximum of 1 star if participants already had some evidence of disease at entry.

# Supplementary Table 3: Extracted studies

	Population	Study Type	Dates of study	Imaging Assessment	Microbiological Assessment	Symptom Assessment	Follow up methods	Transition*	Proportion making transition (time, months)
<b>1. Alling(1)</b> (1955) USA	<ul> <li>Diagnosis of moderate tuberculosis</li> <li>Followed up within the study hospital</li> <li>Sourced from referral from private physician or mass occupational radiographic surveys</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1938 - 1948	Chest X-ray (CXR) reviewed according to NTA <sup>+</sup> criteria with double, independent reading. All "moderate" tuberculosis at baseline	Sputum sent for unknown method. All deemed "arrested" in this data row.	Delineation of symptom status is not well defined but all individuals in this data row were deemed "arrested"	Retrospective collection of routinely collected clinical data from their hospital. Follow up was therefore not systematically done. Definitions of disease groups required repeat CXR and sputum testing over periods of time.	cxr.pos   micro.neg   sympt.unk [arrested‡] to cxr.pos   micro.pos   sympt.unk	<ul> <li>8/58 (60)</li> <li>10/58 (60- 156)</li> </ul>
2. Anastasatu(2 ) (1985) Romania	Smear negative with minimal or moderately advanced pulmonary lesions	Control/ Placebo arm	Unkno wn	CXR	Sputum smear and culture	Not specified but described to be "without radio- clinical symptoms of activity"	Follow up details not clear but authors describe follow up to 24 months, with sputum testing being performed	cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.unk	6/143 (24)
<b>3. Aneja(3)</b> (1979) India	<ul> <li>Symptomatic for TB and abnormal photofluorogram</li> <li>Negative sputum microscopy</li> <li>No TB treatment, or less than 2 weeks of treatment prior to entry into trial</li> <li>Well enough for ambulant care</li> </ul>	Control/ Placebo arm	1968 - 1972	CXR that was double-read ± a third umpire in case of discrepancies	Sputum for microscopy and culture	Review of clinical symptoms e.g. cough	Repeat CXR and spot sputum for microscopy and culture were done at the end of the 2nd, 4th, 6th, 9th and 12th months of follow up	cxr.pos   micro.neg   sympt.pos to cxr.pos   micro.pos   sympt.unk	21/110 (12)
<b>4.</b> Beeuwkes(4) (1942)	Household contacts with at least 6 months of follow up data	Household Contact Study	1933- 1938	CXR	72 hour concentrated sputum sample for microscopy. Some also had	Based on medical history and examination to have been "asymptomatic"	Re-examined 6-12 monthly plus additional unscheduled visits if	cxr.neg   micro.neg  symp.neg to	1/784 (6- 60)

USA					culture and/or		developing	cxr.unk   micro.pos	
					inoculation.		symptoms. Reviews included	sympt.pos cxr.neg   micro.neg	
							medical history and	symp.neg	
							examination, chest x-	Symplice	
							ray and sputum	to	3/784 (6-
							sampling.		60)
								cxr.unk   micro.neg	
								sympt.pos	
								cxr.pos   micro.neg	
								sympt.neg	
								to	3/79 (6-60)
								cxr.unk   micro.pos	
								sympt.pos	
								cxr.pos   micro.neg   sympt.neg	
								symptineg	
								to	5/79 (6-60)
								cxr.unk   micro.neg	
								sympt.pos	
								cxr.pos  . micro.neg	
								sympt.neg	
									13/43 (6-
								to	60)
								cxr.unk   micro.pos	
								sympt.pos	
								cxr.pos   micro.pos	
								sympt.pos	
									10/28 (6-
								to	60)
								cxr.unk   micro.neg	
								sympt.unk	
5.	Patients at study				Sputum sample or		Radiographic,	cxr.pos   micro.neg	
5. Bobrowitz(5,	• Patients at study site with minimal	Clinic/			gastric		mycobacteriological	sympt.unk	
6)	disease on Chest X-	Hospital/	1938 -		concentrates or	Symptoms and	and clinical review		
(1947; 1949)	ray	Sanatorium	1945	CXR	cultures (authors	clinical review	during Sanatorium	to	26/191 (60)
	At least 6 months	Cohort			noted that gastric cultures became		stay but intervals not	cxr.pos   micro.pos	
USA	of follow up data				more frequent		clearly defined	sympt.unk	
	1		I	1	more nequent	1	1	Shiption	

					from 1939				
					onwards)				
6. B <b>orgen(7,8)</b> (1951;1952) Norway	• Age: >15 years • Factory workers who participated in a repeat survey	Occupation al/ Student Screening	1947 - 1949		It is unclear whether systematic sputum testing was done at baseline, irrespective of photofluorograph y results	Clinical review including symptoms such as loss of weight and signs such as pyrexia	Factory workers had repeat survey at 2 years follow up point. Included repeat photofluorography. Also included sputum testing but unclear as to whether this was performed in all or only those with radiographic abnormalities.	cxr.neg   micro.unk   sympt.unk to cxr.pos   micro.pos   sympt.pos cxr.pos  .micro.neg   sympt.pos to cxr.pos   micro.pos   sympt.pos	4/6884 (30) 2/24 (30)
								cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.pos	2/120 (30)
<b>7. Breu(9)</b> (1954) Germany	<ul> <li>Patients that were assessed as part of mass screening in Ludwigsburg, Germany</li> <li>Demonstrated abnormal chest X-ray at baseline but micro negative</li> </ul>	General Community Survey	1949 - 1952	Photofluorogra phy, CXR, tomography	Sputum for culture if either symptomatic or CXR abnormality suggestive of TB (but not all patients were able to produce sputum)	Delineation of symptom status is not well defined. All patients had an ESR performed at baseline.	Followed up "regularly" but interval not specified. Follow up included CXR, CT, microbiology (for sputum, laryngeal swab, gastric lavage)	cxr.pos   micro.pos   sympt.unk to cxr.pos   micro.pos   sympt.unk	48/904 (3- 48)
<b>8. Cowie(10)</b> (1985) South Africa	<ul> <li>New or enlarging apical lesions on 6- monthly Chest X-ray occupational screening</li> <li>Apical lesion still present on repeat Chest X-ray 2 months later</li> <li>Concentrated smear X3 (baseline) and culture X2 (2- months later) of sputum was</li> </ul>	Occupation al/ Student Screening	1979 - 1984	CXR with new or enlarging apical lesions	Early morning sputa for concentrated microscopy and culture	The authors do not comment on the clinical status/symptoms of the cohort	<ul> <li>3-monthly CXRs for</li> <li>3 years followed by 6-monthly until 5 year</li> <li>endpoint in the study</li> <li>Sputum for smear</li> <li>or culture if there was</li> <li>any progression</li> <li>radiographically or if</li> <li>the original lesion</li> <li>was thought to</li> <li>suggest</li> <li>bacteriologically</li> <li>positive disease</li> <li>Histology from</li> </ul>	cxr.pos   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk	88/152 (3- 58)

	negative for MTB • Employee at the Gold Mine						bronchoscopy was also performed in some			
<b>9.</b> Downes(11) (1938) USA	<ul> <li>Resident of Cattaraugus County</li> <li>Diagnosed with active TB at some stage during the cohort years</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1923 - 1935	CXR	Microscopy on sputum (to confirm certain definitions, sputum was also concentrated)	Met the criteria for 'active' disease which was based on symptoms and examination	Retrospective data collection of clinical records, sanatoria outcomes and self- reporting. Data collection included that of mycobacteriology, clinical status and imaging.	cxr.pos   micro.pos   sympt.pos to cxr.pos   micro.neg   sympt.neg	• • •	27/34 2 (12) 104/3 42 (24) 140/3 42 (36) 158/3 42 (48) 171/3 42 (60)
<b>10. Frimodt-</b> <b>Moller(12)</b> (1965) India	<ul> <li>Abnormalities on Chest X-ray at baseline (and deemed probably tuberculous aetioloygy by two reviewers)</li> <li>Negative smear and culture from sputum and larryngeal swab</li> </ul>	Control/ Placebo arm	1960- 1961	CXR deemed probably tuberculous by two readers	Microscopy and culture of sputum and laryngeal swab	Delineation of symptom status is not well-defined	3-monthly follow-ups occurred over a 3 year period including CXR and microbiological assessment	cxr.pos   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk	•	11/86 (12) 18/86 (24) 25/86 (36)
<b>11. Hong</b> <b>Kong Chest</b> <b>Service</b> (13– 16) (1979, 1981, 1981, 1984) HONG KONG	<ul> <li>Age: 15-75 years</li> <li>Radiographic evidence of 'active pulmonary tuberculosis' by a Hong Kong Chest Physician (not those considered fibrotic/inactive)</li> <li>No previous ATT</li> <li>At least 5 sputum smears negative over approximately one week</li> </ul>	Control/ Placebo arm	Not specifi ed	CXR	Microscopy and culture of sputum X 5	Cough, sputum production, haemoptysis	<ul> <li>1-2 sputum specimens for microscopy and culture at monthly reviews in the first year and then quarterly reviews up to 30 months</li> <li>20 CXRs done between baseline and month 60</li> <li>Clinical reports made at each sampling/imaging visit</li> <li>Unscheduled additional reviews</li> </ul>	cxr.pos   micro.neg   sympt.mixed to cxr.pos   micro.pos   sympt.unk	•	40/17 6 (3) 49/17 6 (6) 61/17 6 (12) 67/17 6 (18) 69/17 6 (24) 70/17 6 (30) 71/17 6 (36) 71/17 6 (60)

12. IUAT Committee on Prophylaxis( 17) (1982) Europe 13. Lincoln(18) (1954)	<ul> <li>been stable during the year prior to study entry</li> <li>Positive Mantoux</li> <li>No previous ATT</li> <li>Not previously mycobacteriologicall y positive and not culture positive at entry to the trial</li> <li>No history of prior diagnosis of TB</li> <li>Now Chest X-ray suggestive of minimal TB</li> <li>Followed up within the study hospital for at least one year</li> <li>Sourced from referral from private</li> </ul>	Control/ Placebo arm Clinic/ Hospital/ Sanatorium Cohort	Unkno wn 1937 - 1947	CXR showing fibrotic lesions CXR reviewed according to NTA criteria with double, independent reading. All "minimal"	2 Sputum cultures at entry Sputum sent for unknown method. 128/134 had sputum examination for tubercle bacilli. 112/128 had at	Not well-defined The authors' definition of 'active' disease makes use of the NTA definitions which include symptom activity within their definitions. The majority of those with 'active' disease were also	including sputum culture, CXR and/or vital status was recorded • Records were also reviewed annually to see whether participants had been started on TB treatment Retrospective collection of routinely collected clinical data from their hospital. Follow up was therefore not systematically done. Definitions of disease	cxr.pos   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk cxr.pos   micro.mixed   sympt.pos to cxr.pos   micro.neg   sympt.unk	97/6990 (12-60) • 45/13 4 (24) • 71/13 4 (36) • 80/13 4 (48) • 83/13 4 (60) • 86/13 4 (72) • 87/13 4 (84) • 15/31
USA	physician (due to symptoms or a known TB contact) or from mass occupational radiographic surveys	sician (due to ptoms or a wn TB contact) om mass upational	tuberculosis at baseline in this data row.	least one "positive" sputum by some method.	noted to have self-presented for care rather than having being picked up during general community screening.	groups required repeat CXR and sputum testing over periods of time.	cxr.pos   micro.neg   sympt.unk [arrested‡] to cxr.pos   micro.pos   sympt.unk	$\begin{array}{c}       4 (24) \\       25/31 \\       4 (36) \\       32/31 \\       4 (48) \\       35/31 \\       4 (60) \\       36/31 \\       4 (72) \\       \end{array}$	
<b>14.</b> <b>Manser(19)</b> (1953) Switzerland	<ul> <li>Patients from the study sanatorium's records</li> <li>Over 60 years of age</li> </ul>	Clinic/ Hospital/ Sanatorium Cohort	1941 - 1951	CXR	Sputum or gastric lavage for unspecified method	Symptom questioning, fever, temperature, weight; but the authors do not	Frequency of follow up was not specified, but included physical exam, weight, ESR, CXR/CT, and sputum or gastric lavage	cxr.pos   micro.pos   sympt.unk to	15/40 (6)

						present breakdown of data		cxr.pos   micro.neg   sympt.unk	
<b>15.</b> Marshall(20) (1948) UK	<ul> <li>Acute bilateral pulmonary tuberculosis of presumably recent origin</li> <li>Old-standing disease and disease with thick-walled cavities excluded</li> <li>Bacteriologically proven</li> <li>Unsuitable for collapse therapy</li> <li>15 to 30 years of age</li> </ul>	Control/ Placebo arm	1947 - 1948	CXR	Sputum (direct smear and culture) ± laryngeal swab or gastric lavage if unable to produce (for culture)	General condition, temperature, weight	<ul> <li>All remained admitted to the sanatorium for 6 months and outcomes were assessed at this point</li> <li>Follow up included monthly clinical reviews</li> <li>CXR (by blinded radiologist) and mycobacterial investigations done by clinical team were recorded</li> </ul>	cxr.pos   micro.pos   sympt.pos to cxr.pos   micro.neg   sympt.unk	1/52 (6)
16. National	<ul> <li>Randomly selected households in Bangalore district entered into a mass survey</li> <li>Excluded those with BCG scars</li> </ul>	andomly selected iseholds in galore district General ered into a mass Community yey Survey ccluded those		CXR (this data row: normal or "considerred to be of nontuberculous etiology")	Sputum (spot & overnight) for microscopy and culture in those with abnormal CXR or CXR not interpretable	The authors do not comment on the clinical status/symptoms of the cohort	Surveyed every 18-24 months including: • Photofluorography • Two sputum specimens if any history of abnormal CXR or CXR not interpretable	cxr.neg   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk	<ul> <li>44/31         <ul> <li>490</li></ul></li></ul>
Tuberculosis Institute(21– 28) (1974; 1976; 1976; 1976; 1978; 1978; 1978; 1978; 1982)			y 1961 - 1968					cxr.pos   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk	<ul> <li>23/32 9(18)</li> <li>36/27 1 (60)</li> </ul>
India				CXR				cxr.pos   micro.pos   sympt.unk to cxr.pos   micro.neg   sympt.unk	<ul> <li>86/26 9 (18)</li> <li>70/17 8 (36)</li> </ul>
<b>17.</b> Norregaard(2 9) (1990) Denmark	<ul> <li>Abnormal Chest X- ray</li> <li>Sputum smear- negative</li> </ul>	Control/ Placebo arm	1978 - 1985	CXR	Sputum or gastric lavage for microscopy and culture X 6	Medical history: e.g. cough, haemoptysis, fever	CXR and culture of sputum or gastric lavage monthly for the first three months, followed by every second month	cxr.pos   micro.neg   sympt.mixed to cxr.pos   micro.pos   sympt.neg	6/28 (48)

							for six months and annually thereafter for at least three years. In this data row: "slight or no symptoms" were deemed asymptomatic.	cxr.pos   micro.neg   sympt.mixed to cxr.pos   micro.pos   sympt.pos	2/28 (48)
				CXR that was			Reviewed TB registers for the development of incident TB cases	cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.pos	5/309 (1- 24)
18. Okada(30)	18. Okada(30) (2012)• >10 years of age • Living in survey area • Two culture- negative specimensCambodia• No culture- negative specimens	ing in survey General Community 2002 2004 Survey		deemed "TB suggestive" - CXR that was	Sputum for smear and solid culture X 2	Medical history and examination	Conducted a repeat review at 2 years of all those with abnormal CXR at baseline, including medical history, CXR and two sputum specimens for smear and culture	cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.unk	46/309 (24)
(2012)							Reviewed TB registers for the development of incident TB cases	cxr.neg   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.unk	32/21580 (1-24)
				CXR that was deemed "TB suggestive"			Conducted a repeat review at 2 years of all those with abnormal CXR at baseline, including medical history, CXR and two sputum specimens for smear and culture	cxr.pos   micro.neg   sympt.neg to cxr.neg   micro.neg   sympt.unk	26/309 (24)
19. Orrego Puelma(31) (1945)	<ul> <li>Abnormal CXR of minimal extent</li> <li>Had at least 2 years of follow up</li> </ul>	Clinic/ Hospital/ Sanatorium cohort	Unkno wn	CXR	Sputum and/or gastric washings for microscopy,	Cough, loss of weight, haemoptysis, back pain	Repeat CXR and sputum testing were done at unspecified	cxr.pos   micro.neg   sympt.unk to	18/67 (24)

CHILE	data available for retrospective review				culture and/or inoculation		intervals over the two years	cxr.pos   micro.pos   sympt.unk	
20. Pamra(32) (1971) India	<ul> <li>no history of previous treatment for Tb</li> <li>No manifest tuberculous lesion in any organ other than the lungs</li> <li>No evidence of diabetes or any other non- tuberculous disease</li> <li>Apparent radiological stability of the lesions during the period of observation before inclusion in the study, this period being not less than 3 months or more than 3 years</li> <li>Constantly negative results on direct smear and culture examination of at least 2 sputum and laryngeal swab specimens during the period of observation</li> </ul>	Control/ Placebo arm	1958 - 1968	CXR	At least 2 sputum and laryngeal swab specimens smear and culture negative	Not well- described	<ul> <li>Laryngeal swab culture and CXR were done 3-monthly during year 1</li> <li>Laryngeal swab culture and CXR were done 6-monthly during year 2-5</li> </ul>	cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.pos cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.neg	2/178 (72) 55/178 (72)
<b>21.</b> Puffer(33) (1945)	<ul> <li>Following up at study clinic at the time of study</li> <li>Deemed to have</li> </ul>	Clinic/ Hospital/ Sanatorium	1931 - 1943	CXR (in this data row, all deemed to have apical disease)	As per Opie criteria: "Arrested" or "Apparently arrested" is diagnosed when all symptoms	Review of "physical signs and/or	Outcome for all study participants was assessed at 1 Jan 1943 irrespective of when they started in the study. It is not clear if follow up	cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.pos   sympt.pos	9/261 (62)
USA	"reinfection type" Tuberculosis	cohort		CXR	have disappeared for a period of at least 6 months and the physical signs are those of	symptoms"	review was systematic or only based on routinely collected clinical data. In order to meet	cxr.pos   micro.neg   sympt.neg [arrested‡] to	10/267 (62)

Image: state in the state	
regarded as arrested or, when some uncertainty still exists, the designation "apparently arrested" has	
arrested or, when criteria. some uncertainty still exists, the designation "apparently arrested" has	
some uncertainty still exists, the designation "apparently arrested" has	
still exists, the designation "apparently arrested" has	
designation "apparently arrested" has	
designation "apparently arrested" has	
"apparently arrested" has	
arrested" has	
preferable. When	
the patient first	
comes under	
observation of	
the clinic,	
arrested lesions	
are not	
infrequently	
recognisable only	
by radiological	
ovamination but	
are separable CXI.pos   micro.pos	
from "latent sympt.pos	
locions" hocauco	
CXR they are known to to	92/384 (62)
have passed	
uniougn a period	
of manifest	
disease with the	
usual symptoms	
of pulmonary	
tuberculosis.	
When, however, a	
tuberculous	
pulmonary lesion,	
recognised by	
roentgenographic	
examination, has	
been	
accompanied by	
no symptoms of	
the disease	
discoverable by	
inquiry, but is	
associated with	
physical signs of a	

					healed lesion, such as impaired resonance or diminished breath sound, it should be classified as arrested tuberculosis"				
				CXR deemed 'inactive' tuberculosis or tuberculosis of 'doubtful activity'			• CXR repeated at	cxr.pos   micro.neg   sympt.unk to cxr.pos   micro.pos   sympt.unk	38/319 (12)
22. Sikand(34) (1959) India	Employed as police officer in study setting	Occupation al/ Student Screening	1952 - 1958	CXR deemed 'Negative' for TB	Sputum or laryngeal swab for unknown method	Delineation of symptom status is not well defined	two timepoints: o 17 months and o 5-6 years • Indications and regularity of mycobacteriological testing not clearly described	cxr.neg   micro.unk   sympt.unk to cxr.pos   micro.pos   sympt.unk cxr.neg   micro.unk   sympt.unk	89/11268 (17-69)
								to cxr.pos   micro.neg   sympt.unk	251/11268 (17-69)
<b>23.</b> Styblo(35) (1967) Czechoslovak ia	<ul> <li>15 years and older</li> <li>Resident of study district</li> </ul>	General Community Survey	1961 - 1965	CXR with two blinded, independent reviewers	Microscopy of sputum and culture of sputum/laryngeal swabs on 1-3 occasions in all with symptoms or abnormal CXR and in a random selection not meeting these criteria	Clinical History	<ul> <li>Reviewed monthly if hospitalised</li> <li>If ambulatory, CXR annually ± bacteriology if symptomatic or CXR changes</li> </ul>	cxr.neg   micro.neg   sympt.neg to cxr.unk   micro.pos   sympt.pos cxr.neg   micro.neg   sympt.neg	<ul> <li>17/73 000 (1-12)</li> <li>33/73 000 (1-24)</li> <li>49/73 000 (1-36)</li> <li>66/73 000 (1-48)</li> <li>102/7</li> </ul>
					Cintella			sympt.neg to	3000 (1-12)

								cxr.unk   micro.pos   sympt.unk	•	123/7 3000 (1-24) 168/7 3000 (1-36) 175/7 3000 (1-48)
24. Tuberculosis Society of Scotland(36, 37) (1958, 1963) SCOTLAND	<ul> <li>Age: &gt;15 years</li> <li>European</li> <li>No bacilli on sputum smear or culture</li> <li>Abnormal CXR but of "doubtful activity" with no cavitation</li> <li>No known active extrapulmonary disease</li> <li>Not pregnant/ recently post- partum</li> <li>Not diabetic</li> </ul>	Control/ Placebo arm	1954 - 1959	CXR	Sputum, gastric lavage or laryngeal swab for microscopy and/or culture	Authors noted that "chest radiograph was the only important sign of disease"	<ul> <li>3-monthiner reviews, including weight channels and ESR to and those able produce able produce sputum set and those able produce sputum set and the set and the</li></ul>	CXR, hecks testing b esting e in all le to a ample; swabs c xr.pos   micro.neg   sympt.neg to cxr.pos   micro.neg   to cxr.pos   micro.neg   to cxr.pos   micro.neg   to cxr.pos   micro.neg   sympt.neg to cxr.pos   micro.neg   to cxr.pos   micro.neg   to cxr.pos   micro.neg   to cxr.pos   micro.pos   sympt.neg	9/9	5 (24)

\* Start and end points are labeled with three characteristics or states including a Chest Xray status (i.e. cxr.neg or cxr.pos or cxr.unk), a microbiological status (i.e. micro.neg, micro.pos, micro.unk, or micro.mixed), and a symptom status (i.e. sympt.neg, sympt.pos, sympt.unk or sympt.mixed). In these states, "neg" denotes negative, "pos" denotes positive, "unk" denotes unknown and "mixed" denotes a mixed group.

<sup>+</sup> The National Tuberculosis Association (NTA) developed criteria for assigning a clinical status to individuals with tuberculosis(38). These criteria and nomenclature changed over time but generally included groups such as "apparently cured", "arrested", "apparently arrested", "quiescent", and "active". The definition of these groups included radiographic, microbiological and clinical criteria over defined periods of time.

‡ This group were known to have been microbiologically positive on a prior occasion, then documented arrested disease, followed by a relapse

ATT=Antituberculosis Therapy; IUAT=International Union Against Tuberculosis; NTA=National Tuberculosis Association; UK=United Kingdom; USA=United States of America

# Supplementary Table 4: Descriptors on imaging assessments

Author (Publication Year)	Imaging Assessment	Descriptor/quoted text from study
Country	Assessment	
<b>1. Alling</b> (1955) USA	Inactive	"The clinical status of each person at the time of diagnosis was assessed on the basis of roentgenographic and bacteriologic data collected during the first six months following diagnosisaccording to the Diagnostic Standards (1940 edition) published by the National Tuberculosis Association (NTA)." "Arrested: For six months or more prior to the anniversary, the patient's sputum has been free of acid-fast bacilli and his serial chest roentgenograms have been compatible with stable disease. When more than a year has elapsed between clinic examinations and the chest roentgenograms show a stable lesion, the patient is continued in the arrested category throughout the interim."
<b>2. Anastasatu</b> (1985) Romania	Inactive	"A group with an X-ray lesion extension smaller than 10cm <sup>2</sup> and with no epidemiological risk [and] no "radiological activity"
<b>3. Aneja</b> (1979) India	Active	"They had an abnormal shadow on a chest photofluorogram, read as pulmonary tuberculosis (TBP) by the Medical Officer" "suspected to have active tuberculosis on X -ray evidence on single 70mm photofluorogram"
<b>4. Beeuwkes</b> (1942)	Mixed	"Latent (asymptomatic) lesions of first infection or childhood type were designated as calcified nodules, and latent infiltrations, childhood; latent lesions of reinfection or adult type, as latent apical tuberculosis." "Latent (asymptomatic) infiltrations of either the childhood or adult type could be active (progressive or retrogressive), but they were classified as asymptomatic until the patient had symptoms, or physical signs of disease were demonstrated. At that time the diagnosis was changed to manifest (clinical) disease."
USA	Active	Manifest (clinical) tuberculosis, that which gives rise to physical signs or symptoms or both, was designated as childhood (first infection type) or adult (reinfection type) depending on the usual anatomical and clinical characteristics of the lesion
<b>5. Bobrowitz</b> (1947; 1949) USA	Mixed	"Only patients with minimal tuberculosis according to the classification of the National Tuberculosis Association and with the characteristic roentgenological picture of pulmonary tuberculosis of the reinfection type were acceptable. These cases were further subdivided into four groups, according to the size of the infiltrations. In grouping the patients by type of lesion, we utilized the excellent definitions for the roentgenological character of the infiltration described by Reisner and Downes - Exudative, Productive and fibrotic, Exudative-productive, Fibro- calcific form"
6. B <b>orgen</b> (1951;1952) Norway	Active	"Cases submitted to control examination [were] grouped according to roentgenographic and clinical findings into 10 categories including: Active non-destructive tuberculous pulmonary lesions - This group includes cases with pulmonary infiltrates which, according to the roentgenographic findings (soft, indistinct parenchymal lesions) and clinical findings (elevated temperature, increased sedimentation rate, loss of weight, etc.) were considered active lesions but where direct smears or culture failed to reveal tubercle bacilli in the sputum and after an observation period of 1.5-3.5 years no other etiology could reasonably be assumed."
	Inactive	"Inactive pulmonary lesions - This group includes cases with clear-cut, dense, streak-formed and, sometimes calcified lesions. In these cases the process showed no signs of activity during the observation period"
<b>7. Breu</b> (1954) Germany	Mixed	"Bewusst beschränke ich mich bei der Aufzeigung der Entwicklungsreihen aus der geschlossenen in die bakteriologisch offene Tuberkulose, bzw. auf die angeführten röntgenologischen Erscheinungsformen (=Ia-b-Fälle der Fürsorgestatisik)";"nur [] als Ic/IIa angesprochenen Tuberkulosefälle [], die sich später zu einer ansteckenden Lungentuberkulose entwickelten." Intentionally, in presenting the progression from closed to bacteriological open tuberculosis, meaning the roentgenological appearances (Ia-b-cases of the register); only as Ic/IIa classified cases that later progressed to a contagious tuberculosis. [According to old German tuberculosis classification, where Ia/b open, active on xray and contagious with or without bacteriology; Ic open, active but not contagious, with fuzzy appearance on xray; IIa closed, inactive with clear demarcation of lesion on xray]
8. Cowie (1985)	Active	"New or enlarging apical lung lesions detected by routine 6-monthly chest radiography"

South Africa		
<b>9. Downes</b> (1938)	Active	
USA	(Also micro pos)	Retrospectively captured imaging findings, based on clinical records
<b>10. Frimodt-Moller</b> (1965) India	Active	Cases showing lung pathology on the survey films according to two independent readers were referred for bacteriological examination in the field with laryngeal swab cultures and sputum collection for microscopy and sputum culture as well as for having another 70 mm X-ray film taken. The new film was compared with the former and cases thought to be of a non-tuberculous aetiology, or had only calcified lesions, were excluded. Other cases were ranked according to extent of the parenchymal lesion The pretreatment films of the cases have for the purpose of this report been re-read and classified by the senior author with regard to extent of disease and cavitation according to the pattern of classification used by Fox and Sutherland (1956). The assessor did not know what treatment had been given or the fate of the individual cases studied.
<b>11. Hong Kong Chest Service</b> (1979(13), 1981(14), 1981(15), 1984(16)) HONG KONG	Active	"Patients admitted to the studywere diagnosed at the regular routine meetings of physicians of the Hong Kong Chest Service as having radiologically active pulmonary tuberculosis, not previously treated"
12. IUAT Committee on		
Prophylaxis (1982)	Inactive	"For the purpose of entry to the trial, fibrotic lesions were defined as well-delineated radiographic lesions of probable tuberculous origin, usually in the upper half of the lung, which had been stable during the year prior to entry"
Europe		
<b>13. Lincoln</b> (1954) USA	Inactive	"A review was made of all original diagnoses of minimal pulmonary tuberculosis made by the hospital staff during the years 1937 through 1947. In no case had a diagnosis of pulmonary tuberculosis been previously made" "Two physicians, independently of one another and without knowledge of the subsequent clinical course, classified the diagnostic chest roentgenogram of each case according to the presence of pulmonary tuberculosis and the stage of disease. The classification of the stage of disease was based on the Diagnostic Standards (1940 edition), published by the National Tuberculosis Association (NTA). In the few cases in which there was disagreement, consultation was held to effect a mutually acceptable decision." "Arrested: For six months or more prior to the anniversary, the patient's sputum has been free of acid-fast bacilli and his serial chest roentgenograms have been compatible with stable disease. When more than a year has elapsed between clinic examinations and the chest roentgenograms show a stable lesion, the patient is continued in the arrested category throughout the interim."
<b>14. Manser</b> (1953) Switzerland	Active (Also micro pos)	Retrospectively captured imaging findings, based on clinical records
<b>15. Marshall</b> (1948)	Active (Also micro pos)	Study included patients with acute bilateral pulmonary tuberculosis of presumably recent origin, and patients who were unsuitable for collapse therapy. Old-standing disease and disease with thick-walled cavities excluded. Xrays were reviewed by a blinded radiologist.
<b>16. National Tuberculosis</b> <b>Institute</b> (1974; 1976; 1976; 1976; 1978; 1978; 1978; 1978; 1982) India	Active	"Suggestive of tuberculous aetiology judged to be possibly, probably or definitely active tuberculous"
<b>17. Norregaard</b> (1990) Denmark	Active	"The admission criteria were usually small X-ray shadows compatible with active pulmonary tuberculosis in smear negative patients. This evaluation was made at conference by the consultants All patients had infiltrates in the upper lobe of one or both lungs"

18. Okada (2012)		"A panel of experts composed of two respiratory physicians and/or radiologists made a decision on the final radiological findings. Based on the Japanese
Canala a dia	Active	CXR classification for TB"
Cambodia		"A CXR suggestive of active TB was categorised as 'TB-suggestive CXR'"
19. Orrego Puelma (1945)	Mixed	"Minimum or superficial lesions without apparent cavity, limited to a small area in one or both lungs. The total involvement, ignoring its distribution, should not exceed the equivalent in volume of the lung tissue which lies above the second chondrosternal junction and the spine of the fourth or body of the fifth there are used to a small area in one or both lungs.
CHILE		the fifth thoracic vertebra on one side." "Furthermore, we studied only those cases which had two years' evolution, at least."
		(a) No history of previous treatment for tuberculosis.
<b>20. Pamra</b> (1971)		(b) No manifest tuberculous lesion in any organ other than the lungs.
	Mixed	(c) No evidence of diabetes or any other non-tuberculous disease.
India		(d) Apparent radiological stability of the lesions during the period of observation before inclusion in the study, this period being not less than 3 months or more than 3 years.
		"persons with lesions demonstrable by X-ray examination had no physical signs nor symptoms and gave no history of illness indicative of tuberculosis,
	Mixed	they are classed as latent apical cases"
<b>21. Puffer</b> (1945)	wixed	"The classification of lesions as minimal, moderately advanced and far advanced is in accordance with that recommended by the National Tuberculosis
		Association."
USA		"manifest cases were believed to be arrested at the time of first examination in this clinic."
	Inactive	"The classification of lesions as minimal, moderately advanced and far advanced is in accordance with that recommended by the National Tuberculosis
		Association."
		Inactive Pulmonary Lesions
	Inactive	(i) Sputum negative by all methods or L. S. negative by culture;
<b>22</b> Silver d (1050)	mactive	(ii) Hardish shadows in the skiagrams;
<b>22. Sikand</b> (1959)		(iii) No clinical or laboratory evidence suggestive of activity.
India		Lesions of Doubtful Activity
Inula	Mixed	(i) Small soft infiltrations, stationary of regressive but not progressive;
	wixed	(ii) Primary type of tuberculosis;
		(iii) Known pulmonary cases under successful therapy.
<b>23. Styblo</b> (1967)		
	N/A	Xray negative group
Czechoslovakia		
24. Tuberculosis Society of		"Patients were accepted for the trial if the chest radiograph showed an abnormality considered to be tuberculous, this being the only important sign of
Scotland (1958, 1963)	Mixed	disease"
	wiixeu	"certain conditions also excluded acceptance cavitation demonstrable on an ordinary posteroanterior radiograph"
SCOTLAND		"The clinicians were asked to classify their cases as 'acute' without evidence of fibrosis, or 'chronic', with fibrosis present."

### Supplementary Table 5: Descriptors of cohorts included in the Systematic Review

	n (%) or median (IQR)
Cohort Types, n=34	
Clinical Cohort	9 (24.5)
Control arm of therapeutic intervention	9 (24.5)
General Community Survey	7 (20.6)
Household Contact Study	4 (11.8)
Occupational or Student Screening	5 (14.7)
tudy Location, n=34	
Africa	1 (2.9)
• Asia	11 (32.4)
• Europe	10 (29.4)
South America	1 (2.9)
North America	11 (32.4)
tatus at entry to cohorts, n=34	
Normal Chest X-ray/imaging	4 (11.8)
Abnormal Chest X-ray/imaging	30 (88.2)
<ul> <li>Abnormal Chest X-ray/imaging, where the authors state that the</li> </ul>	15 (44.1)
extent of disease was active	13 (+1.1)
<ul> <li>Abnormal Chest X-ray/imaging, where the authors state that the</li> </ul>	9 (26.5)
extent of disease was inactive/fibrotic	, (20.3)
<ul> <li>Abnormal Chest X-ray/imaging, where the authors state that the</li> </ul>	
extent of disease was "mixed" in this group or they did not	6 (17.6)
describe/specify	20 (02 4)
Microbiological status <sup>+</sup> negative	28 (82.4)
Microbiological status <sup>+</sup> positive	6 (17.6)
<ul> <li>Microbiological status<sup>+</sup> mixed or unknown</li> </ul>	0 (0.0)
Symptomatic‡	7 (20.6)
Asymptomatic <sup>‡</sup>	11 (32.4)
Symptom status <sup>+</sup> mixed or unknown	16 (47.1)
Demographics, n=34	
Sex distribution	
<ul> <li>Equal distribution of males and females</li> </ul>	5 (14.7)
<ul> <li>More females</li> </ul>	8 (23.5)
<ul> <li>More males</li> </ul>	11 (32.4)
<ul> <li>Unknown sex distribution</li> </ul>	10 (29.4)
Age distribution	
o Minimum	5 years
o <b>Maximum</b>	83 years
No details on age distribution specified	10 (29.4)
Local Burden of TB Disease at time of cohort <sup>§</sup> , n=34	
• Low	0 (0.0)
Mid	2 (5.9)
• High	9 (26.5)
Not specified or unknown	23 (67.6)

\* Studies were able to contribute  $\geq 1$  cohort

+ To establish microbiological status, authors used a variety of methods which included sputum (spot or extended collection periods e.g. overnight), laryngeal swabs, and gastric aspirates

+ Symptom status was as per author classification

§ As per World Health Organisation stratification

IQR = Interquartile Range; TB = Tuberculosis

#### Cohorts progressing to bacteriologically positive disease All studies using culture for bacteriological testing

	Progression	Cohort	Follow-up (months)		Proportion [95% CI]
Active					
Frimodt-Moller2, 1965	25	86	36	<b>⊢</b> ∎-	0.10 [0.04, 0.17]
Okada, 2012	51	309	24	H	0.09 [0.06, 0.12]
Cowie, 1985	88	152	58	⊢∎⊣	0.16 [0.11, 0.22]
Norregaard, 1990	8	28	48	i-∎-1	0.07 [0.00, 0.17]
Aneja, 1979	21	110	12	⊢∎⊣	0.19 [0.12, 0.26]
National Tuberculosis Insitute, 1982	36	271	60	ж	0.03 [0.01, 0.05]
Beeuwkes, 1942.2	13	43	33	<b>⊢</b> ∎	0.12 [0.02, 0.21]
Hong Kong Chest Service, 1980	71	176	60	Herl	0.10 [0.05, 0.14]
RE Model for Subgroup (Q = 40.36, df = 7,	p < .01; l <sup>2</sup> = 79.49	%, τ <sup>2</sup> = 0.00	)	٠	0.10 [0.06, 0.14]
Inactive					
UATCP, 1982	97	6990	60	1	0.00 [0.00, 0.00]
Anastasatu, 1985	6	143	24	H I	0.02 [0.00, 0.04]
Puffer, 1945.2	10	267	62		0.01 [0.00, 0.02]
RE Model for Subgroup (Q = 3.02, df = 2,	o = 0.22; l <sup>2</sup> = 26.5%	%, τ <sup>2</sup> = 0.00	)		0.00 [-0.00, 0.01]
Mixed					
Breu, 1954	48	904	25.5		0.03 [0.02, 0.04]
Pamra, 1971	57	178	72		0.06 [0.03, 0.10]
	57 9	178 261	72 62	)=1 #	
Puffer, 1945.1				)=     	0.01 [0.00, 0.02]
Puffer, 1945.1 Bobrowitz, 1949	9	261	62		0.01 [0.00, 0.02]
Puffer, 1945.1 Bobrowitz, 1949 Beeuwkes, 1942.1	9 26	261 191	62 60		0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04]
Puffer, 1945.1 Bobrowitz, 1949 Beeuwkes, 1942.1 Drrego Puelma, 1945	9 26 3	261 191 79	62 60 33	H	0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23]
Pamra, 1971 Puffer, 1945.1 Bobrowitz, 1949 Beeuwkes, 1942.1 Orrego Puelma, 1945 Tuberculosis Society of Scotland, 1963 RE Model for Subgroup (Q = 23.63, df = 6	9 26 3 18 9	261 191 79 67 95	62 60 33 24 24	# ⊨ ⊢=⊣	0.06 [0.03, 0.10] 0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23] 0.05 [0.01, 0.10]
Puffer, 1945.1 Bobrowitz, 1949 Beeuwkes, 1942.1 Orrego Puelma, 1945 Tuberculosis Society of Scotland, 1963	9 26 3 18 9	261 191 79 67 95	62 60 33 24 24	8 ₩ ₩ ¥=1	0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23] 0.05 [0.01, 0.10]
Puffer, 1945.1 3obrowitz, 1949 Beeuwkes, 1942.1 Orrego Puelma, 1945 Tuberculosis Society of Scotland, 1963 RE Model for Subgroup (Q = 23.63, df = 6	9 26 3 18 9 p < .01; l <sup>2</sup> = 81.59	261 191 79 67 95 %, τ <sup>2</sup> = 0.00	62 60 33 24 24	8 ₩ ₩ ¥=1	0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23] 0.05 [0.01, 0.10]
Puffer, 1945.1 3obrowitz, 1949 Beeuwkes, 1942.1 Drrego Puelma, 1945 Tuberculosis Society of Scotland, 1963	9 26 3 18 9 p < .01; l <sup>2</sup> = 81.59 17, p < .01; l <sup>2</sup> = 97	261 191 79 67 95 %, τ <sup>2</sup> = 0.00	62 60 33 24 24	• • • •	0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23] 0.05 [0.01, 0.10] 0.03 [0.01, 0.05]
Puffer, 1945.1 Bobrowitz, 1949 Beeuwkes, 1942.1 Orrego Puelma, 1945 Tuberculosis Society of Scotland, 1963 RE Model for Subgroup (Q = 23.63, df = 6	9 26 3 18 9 p < .01; l <sup>2</sup> = 81.59 17, p < .01; l <sup>2</sup> = 97	261 191 79 67 95 %, τ <sup>2</sup> = 0.00	62 60 33 24 24	• • • • • • • • • • • • • • • • • • •	0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23] 0.05 [0.01, 0.10] 0.03 [0.01, 0.05]
Puffer, 1945.1 Bobrowitz, 1949 Beeuwkes, 1942.1 Orrego Puelma, 1945 Tuberculosis Society of Scotland, 1963 RE Model for Subgroup (Q = 23.63, df = 6	9 26 3 18 9 p < .01; l <sup>2</sup> = 81.59 17, p < .01; l <sup>2</sup> = 97	261 191 79 67 95 %, τ <sup>2</sup> = 0.00	62 60 33 24 24	• • • • •	0.01 [0.00, 0.02] 0.03 [0.01, 0.06] 0.01 [0.00, 0.04] 0.15 [0.06, 0.23] 0.05 [0.01, 0.10] 0.03 [0.01, 0.05]

Supplementary Figure 1: Micro negative to positive, in those studies that used culture

Cohorts progressing to bacteriologically positive disease	
All symptomatic at baseline	

#### Cohorts progressing to bacteriologically positive disease All asymptomatic at baseline

Author(s) and Year	Progression	Cohort	Follow-up (months)		Proportion [95% CI]	Author(s) and Year	Progression	Cohort	Follow-up (months)		Proportion [95% CI]
Active						Active					
						Okada, 2012	51	309	24	H	0.09 [0.06, 0.12]
Borgen, 1952	2	24	30	<b>-</b>	0.04 [0.00, 0.12]						
Aneja, 1979	21	110	12	⊢∎⊣	0.19 [0.12, 0.26]						
Beeuwkes, 1942	13	43	33	⊢∎-	0.12 [0.02, 0.21]						
						Inactive					
RE Model for Subgroup (Q = 7.2)	7, df = 2, p = 0.03; l <sup>2</sup> = 70.8	%, τ <sup>2</sup> = 0.00	))	<b></b>	0.12 [0.03, 0.21]	Anastasatu, 1985	6	143	24	H	0.02 [0.00, 0.04]
						Puffer, 1945.2	10	267	62	•	0.01 [0.00, 0.02]
Inactive						Borgen, 1952	2	120	30	H	0.01 [0.00, 0.02]
						RE Model for Subgroup (Q = 1.08, df = 2, p	p = 0.58; l <sup>2</sup> = 0.0%	$\tau^2 = 0.00$			0.01 [0.00, 0.02]
						Mixed					
						Pamra, 1971	57	178	72	i=i	0.06 [0.03, 0.10]
Mixed						Puffer, 1945.1	9	261	62		0.01 [0.00, 0.02]
						Beeuwkes, 1942	3	79	33	H	0.01 [0.00, 0.04]
						Tuberculosis Society of Scotland, 1963	9	95	24	} <b>=</b> ∣	0.05 [0.01, 0.10]
						RE Model for Subgroup (Q = 11.25, df = 3,	p = 0.01; l <sup>2</sup> = 76.9	9%, τ <sup>2</sup> = 0.0	0)	٠	0.03 [0.00, 0.06]
RE Model for All Studies (Q = 7.2	27, df = 2, p = 0.03; l <sup>2</sup> = 70.8	3%, τ <sup>2</sup> = 0.0	0)	<b>◇</b>	0.12 [0.03, 0.21]	RE Model for All Studies (Q = 34.44, df = 7	7, p < .01; l <sup>2</sup> = 88.9	9%, τ <sup>2</sup> = 0.0	0)	\$	0.03 [0.01, 0.05]
						Test for Subgroup Differences: $Q_M = 10.64$	, df = 2, p = 0.00				
				0 0.25 0.5						0 0.25 0.5	
				Proportion						Proportion	
										· · · · · · · · · · · · · · · · · · ·	

Supplementary Figure 2: Micro negative to positive, stratified by symptom and CXR status at baseline

Author - time(years)	Events	Total		Proportion	95%-CI	Weight (fixed)	Weight (random)
Styblo	116.800000	73000	<u> </u>	0.00	[0;0]	58.0%	44.7%
National Tuberculosis Insitute	19.843861	17936		0.00	[0; 0]	20.6%	26.2%
Beeuwkes	0.363784	784		0.00	0:01	2.1%	4.0%
Okada	30.720912	21580		0.00	[0;0]	19.3%	25.1%
Fixed effect model		113300		0.00	[0;0]	100.0%	
Random effects model				0.00	[0;0]		100.0%
Heterogeneity: $I^2 = 35\%$ , $\tau^2 < 0.0$	001, p = 0.20	I			• • •		
5		C	5e-04 0.001 0.0015				

Supplementary Figure 3: CXR negative and Micro negative, to Micro positive

#### Cohorts progressing to bacteriologically positive disease Only single follow-up studies

#### Cohorts progressing to bacteriologically positive disease Only cumulative follow-up studies

Author(s) and Year	Progression	Cohort	Follow-up (months)		Proportion [95% CI]	Author(s) and Year	Progression	Cohort	Follow-up (months)		Proportion [95% CI]
Active						Active					
Okada, 2012	51	309	24	H	0.09 [0.06, 0.12]	Frimodt-Moller2, 1965	25	86	36	⊦∎⊣	0.10 [0.04, 0.17]
Borgen, 1952.1	2	24	30	i∎⊣	0.04 [0.00, 0.12]	Cowie, 1985	88	152	58	+=-1	0.16 [0.11, 0.22]
Aneja, 1979	21	110	12	⊢∙⊣	0.19 [0.12, 0.26]	Norregaard, 1990	8	28	48		0.07 [0.00, 0.17]
National Tuberculosis Insitute, 1982	36	271	60	H	0.03 [0.01, 0.05]	Hong Kong Chest Service, 1980	71	176	60		0.10 [0.05, 0.14]
Beeuwkes, 1942.2	13	43	33	<b>⊢</b> •-1	0.12 [0.02, 0.21]	Thong Kong Cheat Gervice, 1900	/1	170	00		0.10 [0.00, 0.14]
RE Model for Subgroup (Q = 25.04, df = 4,	p < .01; l <sup>2</sup> = 86.39	%, τ <sup>2</sup> = 0.00)	)	<b>♦</b>	0.09 [0.03, 0.14]	RE Model for Subgroup (Q = 4.27, df = 3,	, p = 0.23; l <sup>2</sup> = 30.8	%, τ <sup>2</sup> = 0.00	)	٠	0.11 [0.08, 0.15]
Inactive						Inactive					
Puffer, 1945.2	10	267	62		0.01 [0.00, 0.02]	Alling, 1955	10	58	156	H	0.02 [0.00, 0.05]
Borgen, 1952.2	2	120	30		0.01 [0.00, 0.02]	Lincoln, 1954	36	314	72	H I	0.02 [0.00, 0.03]
						Sikand, 1959.1	5	167	12	)=	0.03 [0.00, 0.06]
RE Model for Subgroup (Q = 0.01, df = 1, p	= 0.93; I <sup>2</sup> = 0.0%	$\tau^2 = 0.00$ )		1	0.01 [-0.00, 0.02]	IUATCP, 1982	97	6990	60	÷	0.00 [0.00, 0.00]
						Anastasatu, 1985	6	143	24	H	0.02 [0.00, 0.04]
Mixed											
						RE Model for Subgroup (Q = 11.49, df = 4	4, p = 0.02; l <sup>2</sup> = 59.	0%, τ <sup>2</sup> = 0.0	0)	)	0.01 [0.00, 0.03]
Breu, 1954	48	904	25.5		0.03 [0.02, 0.04]						
Puffer, 1945.1	9	261	62		0.01 [0.00, 0.02]	Mixed					
Bobrowitz, 1949	26	191	60	H	0.03 [0.01, 0.06]	<i>Mixea</i>					
Beeuwkes, 1942.1	3	79	33		0.01 [0.00, 0.04]	Sikand, 1959.2	33	152	12	⊢∎⊣	0.22 [0.15, 0.28]
Orrego Puelma, 1945 Tuberculosis Society of Scotland, 1963	18 9	67 95	24 24	⊢∎⊣ }∎i	0.15 [0.06, 0.23] 0.05 [0.01, 0.10]	Pamra, 1971	57	178	72	H	0.06 [0.03, 0.10]
Tuberculosis Society of Scotland, 1965	9	95	24	<b>1</b>	0.05 [0.01, 0.10]						
RE Model for Subgroup (Q = 18.25, df = 5,	p < .01; I <sup>2</sup> = 68.59	$\frac{1}{2}, \tau^2 = 0.00$	)	٥	0.03 [0.01, 0.04]	RE Model for Subgroup (Q = 16.70, df = 1	1, p < .01; l <sup>2</sup> = 94.0	%, τ <sup>2</sup> = 0.01	)	$\diamond$	0.14 [-0.02, 0.29]
RE Model for All Studies (Q = 69.14, df = 1)	2, p < .01; l <sup>2</sup> = 95.	1%, τ <sup>2</sup> = 0.0	00)	٥	0.05 [0.02, 0.07]	RE Model for All Studies (Q = 120.58, df	= 10, p < .01; I <sup>2</sup> = 9	6.9%, τ <sup>2</sup> = 0	1.00)	<b>♦</b>	0.07 [0.03, 0.11]
Test for Subgroup Differences: $Q_{M} = 6.08$ , a	df = 2, p = 0.05					Test for Subgroup Differences: $Q_M = 18.8$	80, df = 2, p = 0.00				
				0 0.25 0.5						0 0.25 0.5	
				Proportion						Proportion	

# Supplementary Figure 4: Micro negative to positive, stratified by structure of follow up

## Full Search Strategy: English

### Filters to be applied within each:

- Languages: English, German & "Unknown language" (latter possible in Pubmed)
- Years: 1895 1960

#### a) Pubmed, Medline and Old Medline

	Category	Search terms
ENGLISH	Population:	Pulmonary tuberculosis OR "Tuberculosis, Pulmonary" [Mesh] OR Incipient tuberculosis OR Phthisis OR Minimal tuberculosis OR Moderate tuberculosis OR Advanced tuberculosis
	Intervention:	Follow up studies OR Course OR Biological Evolution OR After-history OR Supervision OR "Early Diagnosis" [Mesh] OR "Epidemiological Study" [Mesh] OR Epidemiologic study OR Prognosis OR Prospective OR Longitudinal OR Roentgenographic Survey OR Radiography OR Observation OR Progression OR Progress OR Diagnosis

(((((("tuberculosis, pulmonary"[MeSH Terms] OR ("tuberculosis"[All Fields] AND "pulmonary"[All Fields]) OR "pulmonary tuberculosis"[All Fields] OR ("pulmonary"[MeSH Terms] OR ("tuberculosis, Pulmonary"[MeSH]) OR (Incipient[All Fields] AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields])) OR ("tuberculosis, Pulmonary"[MeSH Terms] OR ("tuberculosis"[All Fields])) OR ("tuberculosis, Pulmonary"[MeSH Terms] OR ("tuberculosis"[All Fields])) OR (Moderate[All Fields]) OR "pulmonary tuberculosis"[All Fields]) OR "pulmonary"[MeSH Terms] OR "tuberculosis"[All Fields])) OR (Moderate[All Fields]) OR ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields])) OR (Moderate[All Fields]) OR ("follow-up studies"[MeSH Terms] OR ("follow-up"[All Fields]) OR ("biological evolution"[All Fields]) OR "follow-up studies"[All Fields]) OR Course[All Fields]) OR ("biological evolution"[All Fields] AND "studies"[All Fields]) OR "follow-up studies"[All Fields]) OR ("organization and administration"[All Fields]) OR ("organization"[All Fields]) OR "organization and administration"[All Fields] OR "biological"[All Fields]) OR "supervision"[All Fields]) OR "Early Diagnosis"[MeSH Terms] OR ("epidemiologic studies"[All Fields]) OR ("epidemiologic studies"[All Fields]) OR ("organization and administration"[All Fields]) OR "prognosis"[All Fields]) OR "leids]) OR "leideniologic studies"[All Fields] OR "consis"[All Fields]) OR "epidemiologic studies"[All Fields] AND "studies"[All Fields]) OR "prognosis"[All Fields]) OR "biological evolution"[All Fields] AND "administration"[All Fields] AND "studies"[All Fields]) OR "epidemiologic studies"[MeSH Terms] OR ("biological"[All Fields]) OR "organization and administration"[All Fields] OR "supervision"[All Fields]) OR "administration"[All Fields] OR "supervision"[All Fields]) OR "administration"[All Fields] OR "supervision"[All Fields]) OR "supervision"[All Fields] OR "supervision"[All Fields]) OR "supervision"[All Fields]) OR "supervision"[All Fields]) OR "supervision"[All Fields]) OR "supervisi

### b) EMBASE and EMBASE CLASSIC

	Category	Search terms
ENGLISH	Population:	"Pulmonary tuberculosis" OR "Incipient tuberculosis" OR Phthisis OR Minimal tuberculosis OR Moderate tuberculosis OR Advanced tuberculosis
	Intervention:	"Follow-up stud*" OR "Follow up stud*" OR Course OR "Biological Evolution" OR "After-history" OR Supervision OR Epidemiological Stud* OR Epidemiology OR Prognosis OR Prospective OR Longitudinal OR "Roentgenographic survey" OR Radiography OR Observation* OR Progress* OR Diagnosis

### c) Web of Science

	Category	Search terms
ENGLISH	Population:	"Pulmonary tuberculosis" OR "Incipient tuberculosis" OR Phthisis OR Minimal tuberculosis OR Moderate tuberculosis OR Advanced tuberculosis
	Intervention:	"Follow up stud*" OR "Follow-up stud*" OR "Course" OR "Biological Evolution" OR "After-history" OR Supervision OR "Epidemiological Stud*" OR Epidemiology OR Prognosis OR Prospective OR Longitudinal OR "Roentgenographic Survey" OR Radiography OR Observation* OR Progress* OR Diagnosis

# Full Search Strategy: German

### PUBMED

GERMAN	Population:	Pulmonale Tuberkulose OR Lungentuberkulose OR Lungen-Tuberkulose OR "Tuberkulose, pulmonal, pulmonale" [Mesh] OR anfangende Tuberkulose OR beginnende Tuberkulose OR Beginn der lungentuberkulose OR Fruehinfiltrat OR einsetzende Tuberkulose OR Schwindsucht
		OR Phthisische Entiwicklung* OR Initialherd* OR Tuberculosis inappercepta OR Spitzenschwielen OR Spitzenherd* OR begrenzte* OR Tuberkulinreihenpruefungen OR Lungenschwindsucht OR Entstenhung OR Entwicklung*
	Intervention:	Längsschnittstudie OR Longitudinalstudie OR Verlaufsstudie OR Verlauf OR Entwicklung OR Verlauf OR Nachverfolgung OR Beobachtung OR Frühdiagnose OR Früherkennung OR "epidemiologische Studie" [Mesh] OR Prognose OR prospektiv OR vorausschauend OR longitudinal OR längsschnitt OR Röntgen OR röntgenographisch OR radiographisch OR radiologisch OR Beobachtung OR Betrachtung OR Folge OR Entwicklung OR Progression OR Fortschreitung OR Verlauf OR Fortschritt OR Diagnose

### EMBASE

GERMAN	Population:	"Pulmonale Tuberkulose" OR "Lungentuberkulose" OR "Lungen-Tuberkulose" OR "generalisierte Tuberkulose" OR "disseminierte Tuberkulose" OR "miliare Tuberkulose" OR "anfangende Tuberkulose" OR "beginnende Tuberkulose" OR "einsetzende Tuberkulose" OR Tuberk* OR Schwindsucht
	Intervention:	"Längsschnittstudie" OR "Längsschnitt-studie" OR "Longitudinalstudie" OR "Longitudinal-studie" OR "Verlaufsstudie" OR "Verlaufs-studie" OR Verlauf OR "Entwicklung" OR "Verlauf." OR "Nachverfolgung" OR Beobachtung OR epidemiologische Studie OR Epidemiologie OR Prognose OR Prospektiv OR Vorausschauend OR longitudinal OR längsschnitt OR "Röntgen" OR "röntgenographische Studie" OR "röntgenographische Untersuchung" OR "radiologische Studie" OR "radiologische Untersuchung" OR Radiologie OR Röntgen OR Beobachtung* OR Fortschritt* OR Diagnose

### Web of Science

GERMAN	Population:	"Pulmonale Tuberkulose" OR "Lungentuberkulose" OR "Lungen-Tuberkulose" OR "generalisierte Tuberkulose" OR "disseminierte Tuberkulose" OR "miliare Tuberkulose" OR "anfangende Tuberkulose" OR "beginnende Tuberkulose" OR "einsetzende Tuberkulose" OR Tuberk* OR Schwindsucht
	Intervention:	"Längsschnittstudie" OR "Längsschnitt- studie" OR "Longitudinalstudie" OR "Longitudinal-studie" OR "Verlaufsstudie" OR "Verlaufs-studie" OR "Verlauf" OR "Entwicklung" OR "Nachverfolgung" OR Beobachtung OR "epidemiologische Studie" OR Epidemiologie OR Prognose OR Prospektiv OR Vorausschauend OR longitudinal OR längsschnitt OR verlauf OR "Röntgen" OR "röntgenographische Studie" OR "röntgenographische Untersuchung" OR "radiologische Studie" OR "radiologische Untersuchung" OR Radiologie OR Röntgen OR Beobachtung* OR Fortschritt* OR Diagnose

# PRISMA Checklist(39)

Section/topic	#	Checklist item	Reported on page #
TITLE	<u>.</u>		
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
INTRODUCTION	<u> </u>		
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6,9
METHODS	<u>.</u>		
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	9
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	9
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	9
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	9 & Supplementary
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9-10
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	10-11

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	11
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	10-11
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	12

Page	1	of 2	
гауе		012	

Section/topic	on/topic # Checklist item		Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	27
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	11
RESULTS	-		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	13 (figure 2)
		For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	16-18 & Supplementary
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Figure 3,4 & Supplementary
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Figure 3,4 & Supplementary
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Supplementary figures
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	25

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	26
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	25-27
FUNDING	-		
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	12

## References

- 1. Alling D, Bosworth E, Lincoln N. The after-history of pulmonary tuberculosis: V. Moderately Advanced Tuberculosis. Am Rev Tuberc. 1955;71(4):519–28.
- 2. Anastasatu C, Berceea O, Corlan E. Controlled clinical trial on smear negative, x-ray positive new cases, with the view to establishing if and how to treat them. Bull Int Union Tub. 1985;60:108–9.
- 3. Aneja KS, Gothi GD, Samuel GER. CONTROLLED STUDY OF THE EFFECT OF SPECIFIC TREATMENT ON BACTERIOLOGICAL STATUS OF 'SUSPECT CASES.' Indian J Tuberc. 1979;26:8.
- 4. Beeuwkes H, Hahn RG, Putnam P. A Survey of Persons Exposed to Tuberculosis in the Household1,. Am Rev Tuberc. 1942;29.
- 5. Bobrowitz ID, Hurst A, Martin M. Minimal Tuberculosis; the prognosis and clinical significance of a sanatorium treated group. Am Rev Tuberc. 1947;56(2):16.
- 6. Bobrowitz ID, Hurst A. Minimal Tuberculosis: Problems in Roentgenologic Interpretation. Radiology. 1949 Apr;52(4):519–32.
- 7. Borgen L, Meyer S, Refsum E. Mass photofluorography, tuberculin testing, and BCG vaccination in the district of Aker (Norway) 1947-49. Acta Tuberc Scand. 1951;25(4):327–55.
- 8. Borgen L., Meyer SN., Refsum E. A preliminary report of tuberculin tests and mass chest surveys carried out in Aker. Acta Tuberc Scand Suppl. 1950;26:159–68.
- 9. Breu K. [Public health x-ray diagnosis of closed pulmonary tuberculosis later proved contagious]. Beitrage Zur Klin Tuberk Spezifischen Tuberk-Forsch. 1954;111(5):437–44.

- 10. Cowie L, Langton ME. Diagnosis of sputum smear- and sputum culture-negative pulmonary tuberculosis. SAMJ. 1985;68:1.
- 11. Downes J. A Study of Mortality among Individuals with Active Pulmonary Tuberculosis. Milbank Mem Fund Q. 1938 Jul;16(3):304.
- 12. Frimodt-Moller J, Parthasarathy R, Thomas J. Results of treatment of non-bacillary tuberculosis in a domiciliary treatment prrogramme,-a preliminary report. 1960;
- 13. Hong Kong Chest Service. SPUTUM-SMEAR-NEGATIVE PULMONARY TUBERCULOSIS CONTROLLED TRIAL OF 3-MONTH AND 2-MONTH REGIMENS OF CHEMOTHERAPY. The Lancet. 1979 Jun;313(8131):1361–3.
- 14. Hong Kong Chest Service, Tuberculosis Research Centre, Mad, British Medical Research Council. A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis. Tubercle. 1981 Sep;62(3):155–67.
- 15. Hong Kong Chest Service. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. 1981;
- 16. Hong Kong Chest Service, Centre TR. A Controlled Trial of 2-Month, 3-Month, and 12-Month Regimens of Chemotherapy for Sputum-Smear-Negative Pulmonary Tuberculosis: Results at 60 months. Am Rev Respir Dis. 1984;6.
- 17. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Org. 1982;60(4):555–64.
- 18. Lincoln NS, Bosworth EB, Alling DW. The After-History of Pulmonary Tuberculosis III: Minimal tuberculosis. Am Rev Tuberc. 1954;70(1):17.
- 19. Manser H. [Tuberculosis in aged and its course during sanatorium treatment]. Schweiz Z Tuberk Rev Suisse Tuberc Riv Svizzera Della Tubercolosi. 1953;10(2):65–82.
- 20. Medical Research Council. Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. BMJ. 1948 Oct 30;2(4582):769– 82.
- 21. Chakaraborty, A K, Singh, H, Srikantan, K, Rangaswamy, K R, Krishnamurthy, MS, Stephen, J A. Tuberculosis in a rural population of South India: Report on five surveys. Indian J Tuberc. 1982;29(3):153–67.
- 22. Chakraborty, A K, Gothi, G D, Dwarkanath S, Singh H. Tubercculosis mortality rate in a South Indian rural population. Indian J Tuberc. 1978;25(3).
- 23. Krishnamurthy V, Nair S, Gothi G. A comparison of new cases (incidence cases) who had come from different epidemiological groups in the population. Indian J Tuberc. 1978;25(3).

- 24. Gothi GD, Chakaraborty AK, Jayalakshmi MJ. INCIDENCE OF SPUTUM POSITIVE TUBERCULOSIS IN DIFFERENT EPIDEMIOLOGICAL GROUPS DURING FIVE YEAR FOLLOW UP OF A RURAL POPULATION IN SOUTH INDIA. Indian J Tuberc. 1978;25(2):9.
- 25. Krishnamurthy VV, Nair SS, Gothi GD, Chakraborty AK. Incidence of Tuberculosis among newly infected population and in relation to the duration of infected status. Indian J Tuberc. 1976;23(1).
- 26. Gothi, G D, Chakraborty, A K, Ganapathy, K.T. Five year incidence of tuberculosis and crude mortality in relation to non-specific tuberculin sensitivity. Indian J Tuberc. 1976;23(2).
- 27. Chakraborty AK, Gothi GD. RELAPSES AMONG NATURALLY CURED CASES OF PULMONARY TUBERCULOSIS. Indian J Tuberc. 1976;23(1):6.
- 28. Chakraborty AK. INTERPRETATION OF PHOTOFLUOROGRAMS OF ACTIVE PULMONARY TUBERCULOSIS PATIENTS FOUND IN EPIDEMIOLOGICAL SURVEY AND THEIR FIVE YEAR FATE. Indian J Tuberc. 1974;21:8.
- 29. Norregaard J. Abacillary pulmonary tuberculosis. Tubercle. 1990;71:35-8.
- 30. Okada K, Onozaki I, Yamada N, Yoshiyama T, Miura T, Saint S, et al. Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. :7.
- 31. Orrego Puelma H, Grebe G. Analysis of One Hundred Cases of Minimal Pulmonary Tuberculosis. Dis Chest. 1945 Sep;11(5):375–9.
- 32. Pamra SP, Mathur GP. Effects of Chemoprophylaxis on Minimal Pulmonary Tuberculosis Lesions of Doubtful Activity. Bull World Health Org. 1971;45(5):10.
- 33. Puffer RR, Stewart HC, Gass RS. Tuberculosis according to age, sex, family history, and contact. Am Rev Tuberc. 1945;51(4):295–311.
- 34. Sikand B, Narrain R, Mathur G. Incidence of TB as Judged by Re-surveys. Indian J Tuberc. 1959;6:73–83.
- 35. Styblo K, Dajkova D, Kubik A, Langerova M, Radkovsky J. Epidemiological and Clinical Study of Tuberculosis in the District of Kolin, Czechoslovakia. Bull World Health Org. 1967;37:56.
- 36. Tuberculosis Society of Scotland. A controlled trial of chemotherapy in pulmonary tuberculosis of doubtful activity. Tubercle. 1958 Jun;39(3):129–37.
- 37. Scottish Thoracic Society. A controlled trial of chemotherapy in pulmonary tuberculosis of doubtful activity: Five year follow-up. Tubercle. 1963 Mar;44(1):39–46.

- 38. Long ER, Hopkins FD. History of Diagnostic Standards and Classification of Tuberculosis of the National Tuberculosis Association. Am Rev Tuberc. 1952 Apr;65(4):494–504.
- 39. Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med. 6(7).